MedTrace Logo

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

NCT05591079 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2023-11-21

No results posted yet for this study

Summary

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)

Conditions

  • Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG

CS0159 (Linafexor)

Oral QD

Sponsors & Collaborators

  • Laboratory Corporation of America

    collaborator INDUSTRY

  • Cascade Pharmaceuticals, Inc

    lead OTHER

Principal Investigators

  • Rong Deng · Cascade Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-10
Primary Completion
2023-11-09
Completion
2023-11-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05591079 on ClinicalTrials.gov